Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PKLR | P30613 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12622049 | 0.86 | L3MBTL1 (0.58) | POLBL3MBTL1ALDH1A1KDM4EHCRTR1 | |
| SCHEMBL12626205 | 0.86 | L3MBTL1 (0.58) | POLBSMN1; SMN2L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL13035969 | 0.86 | L3MBTL1 (0.58) | POLBL3MBTL1ALDH1A1KDM4EHCRTR1 | |
| SCHEMBL12626006 | 0.86 | L3MBTL1 (0.58) | POLBL3MBTL1ALDH1A1KDM4EHCRTR1 | |
| SCHEMBL12622042 | 0.86 | L3MBTL1 (0.78) | POLBL3MBTL1ALDH1A1KDM4EHCRTR1 | |
| SCHEMBL12621845 | 0.86 | L3MBTL1 (0.65) | POLBL3MBTL1ALDH1A1PKM | |
| SCHEMBL12622002 | 0.86 | POLB (0.64) | POLBSMN1; SMN2L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL12621953 | 0.85 | POLB (0.68) | POLBSMN1; SMN2L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL12622062 | 0.84 | L3MBTL1 (0.55) | POLBL3MBTL1ALDH1A1KDM4EHCRTR1 | |
| SCHEMBL12621871 | 0.84 | GAA (0.59) | POLBSMN1; SMN2L3MBTL1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661580-B2 | Method of inhibiting tau phosphorylation | CASSAVA SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661580-B2 | Method of inhibiting tau phosphorylation | CASSAVA SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11385221-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210389298-A1 | Alzheimer's Disease Assay in a Living Patient | PAIN THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | US | disclosed |
| US-20210095248-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | PAIN THERAPEUTICS, INC. | 2021-04-01 | — | — | US | disclosed |
| EP-3791875-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | Pain Therapeutics, Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| US-10760052-B2 | Method of inhibiting tau phosphorylation | Cassava Science, Inc. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190271686-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | PAIN THERAPEUTICS, INC. | 2019-09-05 | — | — | US | disclosed |
| US-10363239-B2 | Method for inhibiting growth of cancer cells | PAIN THERAPEUTICS (US) | 2019-07-30 | — | — | US | disclosed |
| US-20190136184-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | CASSAVA SCIENCES, INC. | 2019-05-09 | — | — | US | disclosed |
| WO-2014012054-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATENT | PAIN THERAPEUTICS, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| US-8580809-B2 | Filamin A-binding anti-inflammatory analgesic | PAIN THERAPEUTICS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580808-B2 | Filamin A-binding anti-inflammatory analgesic | Pain Therapeutic, Inc. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580809-B2 | Filamin A-binding anti-inflammatory analgesic | PAIN THERAPEUTICS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580808-B2 | Filamin A-binding anti-inflammatory analgesic | Pain Therapeutic, Inc. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20110105484-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
| US-20110105484-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
| US-20110105547-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
| US-20110105547-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
| WO-2010051476-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | PAIN THERAPEUTICS, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105484-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | FLNA, FLNB, OPRK1 | POLB 2825/4885SMN1; SMN2 3022/4885L3MBTL1 3970/4885 |
| US-10363239-B2 | Method for inhibiting growth of cancer cells | FLNA, FLNB, FSCN1 | POLB 2667/4885SMN1; SMN2 3063/4885L3MBTL1 1041/4885 |
| US-20190136184-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | FLNA, FLNB, MAPT | POLB 2356/4885SMN1; SMN2 641/4885L3MBTL1 1789/4885 |
| US-20110105547-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | FLNA, FLNB, OPRK1 | POLB 2825/4885SMN1; SMN2 3022/4885L3MBTL1 3970/4885 |
| US-10760052-B2 | Method of inhibiting tau phosphorylation | FLNA, FLNB, MAPT | POLB 2356/4885SMN1; SMN2 641/4885L3MBTL1 1789/4885 |
| US-20210095248-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | FLNA, FLNB, MAPT | POLB 2356/4885SMN1; SMN2 641/4885L3MBTL1 1789/4885 |
| US-11661580-B2 | Method of inhibiting tau phosphorylation | FLNA, FLNB, MAPT | POLB 2356/4885SMN1; SMN2 641/4885L3MBTL1 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.